This study explores the distribution of genomic alterations in colorectal cancer (CRC) patients using the Xerna™ TME Panel, which classifies tumors into four subtypes based on RNA sequencing data: Immune Active (IA), Immune Suppressed (IS), Immune Desert (ID), and Angiogenic (A). Analysis of 336 samples revealed that 49.4% were classified as IA or IS, indicating potential responsiveness to immune checkpoint inhibitors. Additionally, 73.5% of patients harbored actionable alterations, suggesting novel combination therapy possibilities. The findings underscore the utility of TME profiling for therapy selection in CRC.

Published at SITC 2023.

Gargi D. Basu1, Janine LoBello1, Snehal G. Thakkar1, Jessica Aldrich1, Matthew Halbert1, Patrick Eimerman1, Cynthia A. Flannery1, Nishitha Therala1, David W. Hall1, Daniel Pointing3, Lea Vohar3, Roman Luštrik3, Luka Ausec3, Mark Uhlik2, Seema Iyer2, Laura Benjamin2, Frederick L. Baehner1

1 Exact Sciences
2 OncXerna Therapeutics
3 Genialis Inc.

Share this story, choose your platform!